ABTEI Looking For New Partner

16 January 1995

German plant-based drugs and natural medicines company ABTEI-Pharma-Vertriebs GmbH has bought back the 25% stake in its capital which has been held by Procordia of Sweden, so reverting to being a family business. However, ABTEI has said that it will seek a new partner to make rapid international growth possible.

ABTEI sales rose from 61 million to 163 million Deutschemarks ($103.5 million) between 1989 and 1994. It has a 22% share of the German non-pharmacy market for its products range and is the market leader in the self-service segment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight